Same Indication

Pembrolizumab vs Ranitidine

Pembrolizumab vs Ranitidine: Overview

This comparison examines the pharmacological differences between Pembrolizumab and Ranitidine.

Mechanism of Action

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Ranitidine: Competitive H2 receptor antagonist.

Pharmacokinetics

Half-life: Pembrolizumab — 26 days; Ranitidine — 2-3 hours.

Chemical Properties

Molecular Formula: Ranitidine — C13H22N4O3S.

Molecular Weight: Ranitidine — 314.4050 g/mol.

Type: Pembrolizumab — Antibody; Ranitidine — Small molecule.